G. Bubley

发表

The Immune Landscape of Cancer

Steven J. M. Jones, James A. Eddy, David L. Gibbs, 2018, Immunity.

Oncogenic Signaling Pathways in The Cancer Genome Atlas.

Steven J. M. Jones, Christopher A. Miller, Joshua M. Stuart, 2018, Cell.

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.

G. Bubley, S. Balk, M. Taplin, 1995, The New England journal of medicine.

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

T. Golub, K. Ross, P. Febbo, 2006, Cancer research.

Possible Risk Factors Associated with Relapse in Patients Treated with Neoadjuvant Chemohormonal Therapy for High Risk Prostate Cancer

M. Regan, G. Bubley, S. Balk, 2011 .

Biology of prostate-specific antigen.

G. Bubley, S. Balk, Y. Ko, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BIOLOGY OF PROSTATESPECIFIC ANTIGEN

G. Bubley, S. Balk, J. Ko, 2003 .

The Molecular Taxonomy of Primary Prostate Cancer

Steven J. M. Jones, Joshua M. Stuart, Richard A. Moore, 2015, Cell.

Subjective endpoints in clinical trials: the case for blinded independent central review

G. Bubley, Bin Yao, R. Walovitch, 2013 .

Pathogenic Germline Variants in 10,389 Adult Cancers.

Steven J. M. Jones, Benjamin J. Raphael, Joshua F. McMichael, 2018, Cell.

Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer

Steven L. Chang, F. Fennessy, V. Laudone, 2021, The Journal of urology.

Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients

Steven J. M. Jones, Christopher A. Miller, Joshua M. Stuart, 2018, Cancer cell.

Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.

E. Small, G. Bubley, S. Balk, 1999, Cancer research.

A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer

P. Kantoff, M. Bhasin, G. Bubley, 2016, Clinical Cancer Research.

Whole Transcriptome Sequencing Reveals Extensive Unspliced mRNA in Metastatic Castration-Resistant Prostate Cancer

Wei Li, Hao Zhao, Zheng Xia, 2014, Molecular Cancer Research.

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.

S. Larson, L. Schwartz, M. Morris, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of hypoxia‐inducible factor‐1α (HIF‐1α) polymorphism as a mutation in prostate cancer that prevents normoxia‐induced degradation

G. Bubley, S. Balk, Xinyu Fu, 2005, The Prostate.

Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.

G. Bubley, S. Balk, M. Taplin, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Comprehensive Characterization of Cancer Driver Genes and Mutations

Steven J. M. Jones, Christopher A. Miller, Joshua M. Stuart, 2018, Cell.

The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.

J. Manola, G. Bubley, J. Yannucci, 2006, The Journal of urology.

Towards enzyme activated antiprostatic agents.

A. D'Amico, G. Bubley, M. O. Mitchell, 2000, Bioorganic & medicinal chemistry letters.

Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.

P. Kantoff, G. Bubley, M. Ernstoff, 2013, Urology.

Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells.

Tao Zhang, G. Bubley, M. Barua, 2006, The American journal of pathology.

A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.

P. Kantoff, W. Oh, G. Bubley, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Eligibility a nd R esponse G uidelines f or P hase I I C linical Trials i n A ndrogen-Indepen dent P rostate C ancer: Recommendations F rom t he P rostate-Specifi c A ntigen Working G roup

B. Freidlin, H. Scher, W. Oh, 1999 .

A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer.

S. Taneja, E. Small, G. Bubley, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists.

R. Parker, G. Bubley, S. Greenspan, 2001, The Journal of clinical endocrinology and metabolism.

Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.

Steven L. Chang, K. Pienta, W. Ellis, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.

P. Kantoff, A. Kibel, S. Signoretti, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Models for prostate cancer chemoprevention.

G. Bubley, 2003, Clinical prostate cancer.

Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer.

John T. Wei, J. Aronovitz, R. Dunn, 2011, The Journal of urology.

Detection of sequence-specific antitumor alkylating agent DNA damage from cells treated in culture and from a patient.

B. Teicher, G. Bubley, G. K. Ogata, 1994, Cancer research.

Combination of etanidazole with cyclophosphamide and platinum complexes

B. Teicher, G. Bubley, L. Shulman, 2004, Cancer Chemotherapy and Pharmacology.

Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.

C. Coleman, B. Teicher, G. Bubley, 1991, Cancer research.

Neoadjuvant Enzalutamide Prior to Prostatectomy

P. Kantoff, P. Nelson, G. Haas, 2016, Clinical Cancer Research.

Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide

M. Loda, G. Bubley, S. Balk, 2017, Clinical Cancer Research.

Effect of a HIF-1 Alpha Polymorphism on the Incidence and Prostate Cancer

G. Bubley, 2007 .

Hypoxia‐inducible factor‐1α (HIF‐1α) gene polymorphisms, circulating insulin‐like growth factor binding protein (IGFBP)‐3 levels and prostate cancer

M. Stampfer, J. Gaziano, G. Bubley, 2007 .

Hypoxia‐inducible factor‐1α (HIF‐1α) gene polymorphisms, circulating insulin‐like growth factor binding protein (IGFBP)‐3 levels and prostate cancer

M. Stampfer, J. Gaziano, G. Bubley, 2007 .

Microwave expedited synthesis of 5-aminocamptothecin analogs: Inhibitors of hypoxia inducible factor HIF-1alpha.

G. Bubley, Graham B Jones, J. Torregrossa, 2006, Bioorganic & medicinal chemistry letters.

An approach to heterobifunctional poly(ethyleneglycol) bioconjugates.

G. Bubley, M. Amiji, D. Shenoy, 2005, Bioorganic & medicinal chemistry letters.

Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers.

P. Iversen, G. Bubley, G. Devi, 2004, The Journal of urology.

Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial

G. Rosner, C. Drake, E. Antonarakis, 2017, Clinical Cancer Research.

Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer.

M. Regan, G. Bubley, M. Ernstoff, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Minimal effect of a low-fat/high soy diet for asymptomatic, hormonally naive prostate cancer patients.

C. Mantzoros, M. Regan, G. Bubley, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Repurposed Drugs for Prostate Cancer.

G. Bubley, Wenxin Xu, 2019, Cancer journal.

Dutasteride for the treatment of prostate-related conditions

G. Bubley, S. Slater, C. Dumas, 2012, Expert opinion on drug safety.

Cancer Therapy : Clinical Phase II Study of Androgen Synthesis Inhibition with Ketoconazole , Hydrocortisone , and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer

P. Kantoff, C. Mantzoros, W. Oh, 2009 .

Phase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer

P. Kantoff, C. Mantzoros, W. Oh, 2009, Clinical Cancer Research.

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Susan Halabi, Ethan Basch, P. Kantoff, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.

D. Rosenthal, G. Bubley, S. Come, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance.

M. Regan, G. Bubley, L. Werner, 2011, The Journal of urology.

Multicenter Phase 2 Trial of the Hsp-90 Inhibitor, IPI-504 (retaspimycin hydrochloride), in Patients with Castration-Resistant Prostate Cancer

W. Oh, M. Galsky, S. Srinivas, 2011 .

Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.

P. Nelson, G. Bubley, S. Balk, 2011, Cancer research.

Phase II multicenter study of chemotherapy (chemo)-naive castration-resistant prostate cancer (CRPC) not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone.

E. Small, G. Bubley, C. Logothetis, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer.

G. Bubley, M. Taplin, T. Shuster, 2001, Seminars in oncology.

Serum levels of insulin-like growth factor-1 and insulin-like growth factor-1 binding proteins after radical prostatectomy.

C. Mantzoros, M. Regan, G. Bubley, 2002, The Journal of urology.

Safety, Pharmacokinetics, and Biological Pharmacodynamics of the Immunocytokine EMD 273066 (huKS-IL2): Results of a Phase I Trial in Patients with Prostate Cancer

C. Redfern, G. Bubley, T. Dahl, 2004, Journal of immunotherapy.

Taxane resistance in prostate cancer is mediated by decreased drug-target engagement.

G. Bubley, P. Giannakakou, E. Corey, 2020, The Journal of clinical investigation.

High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy.

G. Bubley, S. Balk, M. Taplin, 1998, The Journal of urology.

Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists.

R. Parker, G. Bubley, Parker Ra, 2001, The Journal of clinical endocrinology and metabolism.

Association Between Androgen Receptor Splice Variants and Prostate Cancer Resistance to Abiraterone and Enzalutamide.

G. Bubley, S. Balk, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hormones and Diet: Low Insulin-like Growth Factor-1 But Normal Bioavailable Androgens in Vegan Men.

G. Bubley, 2000 .

The idiopathic hypereosinophilic syndrome.

G. Bubley, P. Weller, 1994, Blood.

Effect of acyclovir on radiation- and chemotherapy-induced mouth lesions

C. Crumpacker, G. Bubley, L. Schnipper, 1989, Antimicrobial Agents and Chemotherapy.

Benefit of Adjuvant Radiation Therapy for Localized Prostate Cancer with a Positive Surgical Margin.

G. Bubley, 2000 .

Comprehensive Characterization of Cancer Driver Genes and Mutations

Steven J. M. Jones, Christopher A. Miller, Joshua M. Stuart, 2018, Cell.

Association between prostate cancer and serum testosterone levels

G. Bubley, W. DeWolf, S. Rosen, 2002, The Prostate.

Repair of DMA following Incorporation of 1-ÃŸ-o-Arabinof uranosy Icytosine into Herpes Simplex Virus Type I1

C. Crumpacker, G. Bubley, L. Schnipper, 2006 .

Repair of DNA following incorporation of 1-beta-D-arabinofuranosylcytosine into herpes simplex virus type 1.

C. Crumpacker, G. Bubley, L. Schnipper, 1984, Cancer research.

Viral infections and cancer.

G. Bubley, L. Schnipper, 1990, Comprehensive therapy.

Phase II multicenter study of abiraterone acetate (AA) plus prednisone therapy in docetaxel-treated castration-resistant prostate cancer (CRPC) patients (pts): Impact of prior ketoconazole (keto).

H. Scher, G. Bubley, D. Danila, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Spectrum of cis‐diamminedichloroplatinum(II)‐induced mutations in a shuttle vector propagated in human cells

B. Teicher, G. Bubley, B. P. Ashburner, 1991, Molecular carcinogenesis.

Loss of DNA mismatch repair facilitates reactivation of a reporter plasmid damaged by cisplatin

B. Teicher, G. Bubley, S. Aebi, 1999, British Journal of Cancer.

Dramatic and prolonged PSA response after retreatment with a PSA vaccine.

M. Regan, G. Bubley, A. Rojan, 2013, Clinical genitourinary cancer.

Is the flare phenomenon clinically significant?

G. Bubley, G. Bubley, 2001, Urology.

Loss of IFN-γ Production by Invariant NK T Cells in Advanced Cancer1

G. Bubley, S. Balk, Y. Koezuka, 2001, The Journal of Immunology.

Outcomes of Post-Neoadjuvant Intense Hormone Therapy and Surgery for High Risk Localized Prostate Cancer: Results of a Pooled Analysis of Contemporary Clinical Trials

A. Kibel, G. Bubley, M. Taplin, 2021, The Journal of urology.

Frequent abnormalities of TSG101 transcripts in human prostate cancer

G. Bubley, Zijie Sun, S. Balk, 1997, Oncogene.

A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802.

R. DiPaola, L. Butterfield, G. Bubley, 2015, European urology.

Regional loss of chromosome 6 in two urological malignancies.

J. Richie, J. Seidman, G. Bubley, 1989, Cancer research.

Testicular vs adrenal sources of hydroxy-androgens in prostate cancer.

G. Bubley, S. Balk, I. Blair, 2017, Endocrine-related cancer.

Phase II study of Enzalutamide with radiation therapy for intermediate risk prostate cancer: A phase 2 study.

I. Kaplan, G. Bubley, M. Taplin, 2021, International journal of radiation oncology, biology, physics.

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

B. Freidlin, H. Scher, W. Oh, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of mifepristone (RU‐486) in castration‐resistant prostate cancer, with a correlative assessment of androgen‐related hormones

J. Manola, P. Kantoff, C. Mantzoros, 2008, BJU international.

Effects of Bloom's syndrome fibroblasts on genetic recombination and mutagenesis of herpes simplex virus type 1

G. Bubley, L. Schnipper, 1987, Somatic cell and molecular genetics.

Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984

M. Loda, E. V. Van Allen, P. Glazer, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade

P. Kantoff, P. Nelson, A. Kibel, 2018, Prostate Cancer and Prostatic Diseases.

Accuracy of endorectal magnetic resonance/transrectal ultrasound fusion for detection of prostate cancer during brachytherapy.

B. Bloch, I. Kaplan, N. Rofsky, 2013, Urology.

Is the flare phenomenon clinically significant? Commentary

M. Gleave, J. Trachtenberg, G. Bubley, 2001 .

RIBAVIRIN ENTERS CEREBROSPINAL FLUID

C. Crumpacker, G. Bubley, S. Hussey, 1986, The Lancet.

Her-2-neu expression and progression toward androgen independence in human prostate cancer.

J. Manola, M. Loda, P. Kantoff, 2000, Journal of the National Cancer Institute.

Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance

P. Nelson, E. V. Van Allen, J. Lang, 2021, Clinical Cancer Research.

Title: Phase 2 multicenter study of enzalutamide in metastatic castration resistant prostate cancer to identify mechanisms driving resistance Authors List:

P. Nelson, J. Lang, G. Bubley, 2021 .

Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors

M. Loda, P. Kantoff, P. Nelson, 2014, Clinical Cancer Research.

mRNA in Metastatic Castration-Resistant Prostate Cancer Whole Transcriptome Sequencing Reveals Extensive Unspliced

Hao Zhao, G. Bubley, Wei Li, 2014 .

Phase II trial of RAD001 and bicalutamide for castration‐resistant prostate cancer

Aymen Elfiky, Geoffrey Buckle, P. Kantoff, 2012, BJU international.

Biology o f P rostate-Specifi c A ntigen

G. Bubley, S. Balk, Y. Ko, 2003 .

Bicalutamide Functions as an Androgen Receptor Antagonist by Assembly of a Transcriptionally Inactive Receptor*

G. Bubley, S. Balk, Michael L Lu, 2002, The Journal of Biological Chemistry.

Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium

I. Leav, G. Bubley, S. Balk, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Lack of Effect of Aminoglutethimide and Hydrocortisone Added to High-Dose Bicalutamide for Androgen-Independent Prostate Cancer

G. Bubley, S. Balk, M. Taplin, 2001 .

Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor.

G. Bubley, A. Chott, Zijie Sun, 1999, The American journal of pathology.

Prostate cancer in a transgender woman 41 years after initiation of feminization.

I. Kaplan, N. Rofsky, G. Bubley, 2006, JAMA.

Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer

B. Neel, G. Bubley, S. Balk, 2007, Cancer biology & therapy.

Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1

G. Bubley, S. Balk, Xin Yuan, 2006, Proceedings of the National Academy of Sciences.

Incorporation of 1-beta-D-arabinofuranosylcytosine into DNA and mutagenesis of herpes simplex virus type 1

C. Crumpacker, G. Bubley, L. Schnipper, 1986, Antimicrobial Agents and Chemotherapy.

Incorporation of 1-3-D-Arabinofuranosylcytosine into DNA and Mutagenesis of Herpes Simplex Virus Type 1

C. Crumpacker, G. Bubley, L. Schnipper, 2022 .

Inhibition of HSV-transformed murine cells by nucleoside analogs, 2'-NDG and 2'-nor-cGMP: mechanisms of inhibition and reversal by exogenous nucleosides.

C. Crumpacker, G. Bubley, S. Oliver, 1985, Virology.

Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context

Clement Adebamowo, Ritika Kundra, Steven J. M. Jones, 2018, Cell reports.

Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA.

M. Rubin, Botoul Maqsodi, Wen Yang, 2009, Urology.

Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4

Wei Li, G. Bubley, M. Sanda, 2017, Clinical Cancer Research.

A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer

M. Loda, W. Gerald, J. Clohessy, 2013, Nature Genetics.

MUC1 oncoprotein is a druggable target in human prostate cancer cells

L. Yin, G. Bubley, D. Kufe, 2009, Molecular Cancer Therapeutics.

Clonal progression of prostate cancers from Gleason grade 3 to grade 4.

G. Bubley, S. Balk, A. Sowalsky, 2013, Cancer research.

Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer

A. Wyatt, T. Choueiri, M. Morris, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer

G. Bubley, S. Trostel, S. Balk, 2019, bioRxiv.

Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations.

M. Loda, P. Nelson, M. Bhasin, 2018, Cancer research.

Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer

Glenn C. Gaviola, W. Hahn, S. Carter, 2017, JCO precision oncology.

Fatty acid synthase expression defines distinct molecular signatures in prostate cancer.

P. Febbo, M. Loda, G. Bubley, 2003, Molecular cancer research : MCR.

Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.

J. Richie, M. Loda, P. Kantoff, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): Results of a randomized phase II study.

J. Richie, M. Loda, P. Kantoff, 2012 .

Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies

T. Choueiri, G. Sonpavde, G. Bubley, 2020, Cancer.

Detection of circulating tumor cells in men with localized prostate cancer.

P. Kantoff, I. Kaplan, G. Bubley, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hormonal predictors of prostate cancer: a meta-analysis.

C. Mantzoros, G. Bubley, T. Shaneyfelt, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial

A. Renshaw, A. D'Amico, P. Kantoff, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of the Transcription Factor Single-Minded Homologue 2 as a Potential Biomarker and Immunotherapy Target in Prostate Cancer

Manoj Bhasin, Martin G Sanda, Mark A Rubin, 2009, Clinical Cancer Research.

Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer.

G. Bubley, G. Wilding, J. Kolesar, 2013, Urologic oncology.

Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer

A. Einstein, G. Bubley, E. Ette, 2003, Cancer Chemotherapy and Pharmacology.

A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).

M. Erlander, G. Bubley, L. Werner, 2019, Journal of Clinical Oncology.

Treatment of metastatic prostate cancer. Lessons from the androgen receptor.

G. Bubley, S. Balk, 1996, Hematology/oncology clinics of North America.

A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone‐refractory prostate cancer who are refractory to docetaxel

W. Oh, G. Bubley, Jiaoti Huang, 2008, Cancer.

Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer.

M. Gross, G. Bubley, G. Wilding, 2012, Clinical genitourinary cancer.

Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response

E. Small, G. Bubley, C. Logothetis, 2011, Clinical Cancer Research.

Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer.

P. Kantoff, W. Oh, R. DiPaola, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Complementary and alternative medicines in prostate cancer: from bench to bedside?

G. Bubley, S. Klempner, 2012, The oncologist.

Pericardial tamponade associated with myeloid metaplasia

G. Bubley, P. Come, R. Thurer, 1983, American journal of hematology.

Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.

P. Kantoff, T. Choueiri, G. Sonpavde, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of DNA conformation on cisplatin adduct formation.

B. Teicher, G. Bubley, S. Patierno, 1996, Biochemical pharmacology.

An up-to-date evaluation of abiraterone for the treatment of prostate cancer

G. Bubley, Jason Shpilsky, Julia S Stevens, 2021, Expert opinion on pharmacotherapy.

Efficacy of Therapies After Galeterone in Patients With Castration‐resistant Prostate Cancer

E. Heath, G. Bubley, L. Werner, 2017, Clinical genitourinary cancer.

CARCINOGENESIS: Chromium(VI) treatment of normal human lung cells results in guanine-specific DNA polymerase arrest, DNA-DNA cross-links and S-phase blockade of cell cycle

G. Bubley, S. Patierno, Jian Xu, 1996 .

TRA-1-60-positive/CD45low cells found in the peripheral blood of prostate cancer patients with metastatic disease – A proof-of-concept study

Sangyoon J. Han, G. Danuser, J. Shay, 2020, Heliyon.

Cancer Therapy: Preclinical Identification of the Transcription Factor Single-Minded Homologue 2 as a Potential Biomarker and Immunotherapy Target in Prostate Cancer

M. Rubin, M. Bhasin, T. Libermann, 2009 .

A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer.

E. Small, G. Bubley, B. Rini, 2007, Clinical genitourinary cancer.

Hypoxia-inducible factor-1alpha (HIF-1alpha) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer.

M. Stampfer, J. Gaziano, G. Bubley, 2007, The Prostate.

Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation.

G. Bubley, S. Balk, Xinyu Fu, 2005, The Prostate.

Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: Potentiation by Cox‐2 inhibition

G. Bubley, V. Sukhatme, J. Supko, 2005, International journal of cancer.

MUC 1 oncoprotein is a druggable target in human prostate cancer cells

L. Yin, G. Bubley, D. Kufe, 2009 .

Hypoxia‐inducible factor‐2α: effect on radiation sensitivity and differential regulation by an mTOR inhibitor

G. Bubley, V. Sukhatme, S. Balk, 2008, BJU international.

An image contrast agent selectively activated by prostate specific antigen.

A. D'Amico, G. Bubley, C. Crasto, 2006, Bioorganic & medicinal chemistry.

The impact of pretreatment PSA on risk stratification in men with Gleason 6 prostate cancer: Implications for active surveillance.

G. Bubley, B. Gershman, P. Chang, 2021, Urologic oncology.

Phase II study of nivolumab and ipilimumab for advanced bladder cancer of variant histologies (BCVH).

T. Choueiri, G. Sonpavde, G. Bubley, 2019, Journal of Clinical Oncology.

Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy.

J. Manola, P. Kantoff, W. Oh, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer

P. Kantoff, G. Bubley, J. Rosenberg, 2015, Cancer.

Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer.

W. Oh, M. Galsky, S. Srinivas, 2011, Urology.

Prostasol and venous thromboembolism.

G. Bubley, J. Clement, 2008, Urology.

Imatinib-induced regression of AIDS-related Kaposi's sarcoma.

L. Pantanowitz, William B. Weeden, G. Bubley, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intravesical mitomycin therapy for stage T1 and tis high-grade squamous cell carcinoma of the bladder.

G. Bubley, R. Kacker, W. DeWolf, 2014, Clinical genitourinary cancer.

Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer.

J. Manola, P. Kantoff, W. Oh, 2004, Urology.

Biomarker analysis from a randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC).

G. Shapiro, E. Swisher, G. Bubley, 2021 .

Phase II study of nivolumab and ipilimumab for advanced rare genitourinary cancers.

T. Choueiri, G. Sonpavde, G. Bubley, 2020, Journal of Clinical Oncology.

637P Biochemical response (PSA0) and testosterone (T) recovery in Metacure, a multi-arm multi-modality (MM) therapy (tx) for very high risk localized (HRL) and low volume metastatic (LVM) prostatic adenocarcinoma

J. Eastham, I. Kaplan, A. Kibel, 2021, Annals of Oncology.

Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade

P. Kantoff, P. Nelson, A. Kibel, 2018, Prostate Cancer and Prostatic Diseases.

Abstract CT161: A Phase II study of the polo-like kinase (PLK1) inhibitor onvansertib in combination with abiraterone (abi) and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)

M. Erlander, G. Bubley, L. Werner, 2019, Clinical Trials.

Phase II trial of RAD001 (R) and bicalutamide (B) for castration-resistant prostrate cancer (CPRC).

P. Kantoff, W. Oh, G. Bubley, 2010 .

A phase II multicenter study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy with pegfilgrastim support in patients (pts) muscle-invasive urothelial cancer (MIUC): Safety, pathologic, radiologic, and molecular correlates.

S. Signoretti, G. Bubley, G. Steele, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine on DNA repair and mutagenesis of herpes simplex virus type 1.

C. Crumpacker, E. De Clercq, G. Bubley, 1987, Virology.

Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer.

J. Manola, P. Kantoff, W. Oh, 2007, The Journal of urology.

Testosterone Therapy in Men with Biochemical Recurrence and Metastatic Prostate Cancer: Initial Observations

G. Bubley, A. Morgentaler, A. Abello, 2021, Androgens: Clinical Research and Therapeutics.

708: A Phase Ib study of BKM120 combined with abiraterone acetate for castrate-resistant, metastatic prostate cancer

M. Loda, P. Kantoff, L. Cantley, 2014 .

Differences in in vivo and in vitro sequence-specific sites of cisplatin-DNA adduct formation and detection of a dose-response relationship.

B. Teicher, G. Bubley, T. Kusumoto, 1994, Biochemical pharmacology.

Identification of cis-diamminedichloroplatinum(II) adducts in DNA from drug-treated human cell nuclei.

B. Teicher, G. Bubley, S. Balk, 1992, BioTechniques.

Medical Oncology Prostasol and Venous Thromboembolism

G. Bubley, J. Clement, 2008 .

Prostate cancer in the older man.

G. Bubley, Y. Ko, 2001, Oncology.

The Immune Landscape of Cancer.

James A. Eddy, David L. Gibbs, Christopher A. Miller, 2018, Immunity.

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.

S. Larson, L. Schwartz, M. Morris, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer

P. Kantoff, C. Mantzoros, W. Oh, 2009, Clinical Cancer Research.

Neoadjuvant Enzalutamide Prior to Prostatectomy

P. Kantoff, P. Nelson, G. Haas, 2016, Clinical Cancer Research.

Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4

Wei Li, G. Bubley, M. Sanda, 2017, Clinical Cancer Research.

Clonal progression of prostate cancers from Gleason grade 3 to grade 4.

G. Bubley, S. Balk, Huihui Ye, 2013, Cancer Research.

Identification of the Transcription Factor Single-Minded Homologue 2 as a Potential Biomarker and Immunotherapy Target in Prostate Cancer

M. Rubin, M. Bhasin, T. Libermann, 2009, Clinical Cancer Research.

Effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine on the proliferation of herpes simplex virus type 1-transformed and thymidine kinase-deficient mouse cells.

C. Crumpacker, E. De Clercq, G. Bubley, 1983, Virology.

Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide

M. Loda, G. Bubley, S. Balk, 2017, Clinical Cancer Research.

Phase II study of low dose (LD) and high dose (HD) premarin in androgen independent prostate cancer (AIPC).

J. Manola, P. Kantoff, W. Oh, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Challenge of Herbal Therapies for Prostate Cancer

G. Bubley, R. Bhatt, 2008, Clinical Cancer Research.

The Challenge of HerbalTherapies for Prostate Cancer 55 Commentary on Singh et al . , p . 7773

G. Bubley, S. Bhatt, 2008 .